Drug Hunter, Inc.

Based in the US, Drug Hunter, Inc. specializes in drug discovery, providing a suite of services designed to enhance pharmaceutical development efficiency and effectiveness, focusing on critical therapeutic areas. Founded in 2018 and headquartered in Portland, US, Drug Hunter, Inc. is dedicated to advancing drug research and development.

The company has engaged in one deal as of September 2025. Notably, it has undergone a strategic pivot to enhance service offerings in response to market demands. The founder of Drug Hunter has a history in the pharmaceutical sector, although additional details about prior companies are not specified. Drug Hunter specializes in drug discovery, offering a comprehensive range of services that enhances the efficiency and effectiveness of pharmaceutical development.

The core offerings include preclinical research services, medicinal chemistry, and advanced analytics utilizing artificial intelligence and machine learning. These services streamline the drug discovery process from hit identification to lead optimization, aiming to support pharmaceutical and biotechnology clients focusing on areas such as oncology, neurodegenerative diseases, and autoimmune disorders. Drug Hunter’s services are employed in major pharmaceutical markets globally, including North America, Europe, and parts of Asia, providing tailored solutions for diverse therapeutic challenges. Drug Hunter's revenue is primarily generated through B2B partnerships with pharmaceutical and biotech firms.

Their business model is centered around service agreements, which may involve fixed fees for specific research projects and ongoing retainer contracts for long-term partnerships. Clients pay for services on a project basis, encompassing various phases of drug development, from early research to clinical trial support, with pricing structures designed to align with client objectives and projects’ complexity. In September 2025, Drug Hunter, Inc. raised USD 6.

04 million seed funding led by new investor Teamworthy Group. Other unspecified investors also participated in the round. The funding will be utilized to further the company's goal of providing scientists and research leaders with valuable insights to confidently develop future medicines. The company plans to launch new products aimed at enhancing drug discovery processes and is exploring expansion into new markets, targeting both Europe and parts of Asia by late 2026.